Core Viewpoint - Enhua Pharmaceutical has entered into exclusive commercial cooperation agreements with Green Leaf Pharmaceutical and its subsidiary, allowing Enhua to promote and sell three long-acting injectable antipsychotic products in mainland China, marking a significant strategic partnership in the CNS field [1][2]. Group 1: Agreement Details - Enhua's subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., will receive exclusive rights to promote and sell three products: Risperidone microspheres (Riketu®), Paliperidone palmitate injection (Ruibailai®), and Paliperidone palmitate injection (Meibiru®) [1]. - Enhua will pay a one-time non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaao [1]. - The agreement stipulates that Enhua must achieve a minimum sales target of 2.7 billion RMB (approximately $400 million) for the licensed products between 2026 and 2035 [1]. Group 2: Strategic Importance - The exclusive authorization for these three long-acting injectables creates a differentiated product portfolio that addresses the treatment needs of schizophrenia patients at all stages of the disease [2]. - This strategic collaboration between two leading companies in the CNS field is expected to enhance the market presence of these products in primary healthcare centers, facilitating standardized treatment for more patients and reducing the burden of the disease [2].

Core Viewpoint - Enhua Pharmaceutical has entered into exclusive commercial cooperation agreements with Shandong Green Leaf Pharmaceutical and its subsidiary, allowing Enhua to promote and sell three long-acting antipsychotic injectable products in mainland China [1] Group 1: Agreement Details - Enhua's subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., will receive exclusive rights to promote and sell three products: Risperidone microspheres (Rui Ketuo®), Paliperidone palmitate injection (Rui Bailai®), and Paliperidone palmitate injection (Mei Bi Rui®) [1] - Enhua will make a one-time non-refundable payment of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaao as consideration for the rights and licenses granted under the agreement [1] - Enhua is expected to achieve a total sales revenue of no less than 2.7 billion RMB (including tax) for the cooperative products from 2026 to 2035 [1] Group 2: Financial Arrangements - Green Leaf Pharmaceutical and Green Leaf Jiaao will pay Enhua service fees based on the procurement and sales performance of the licensed products [1]

Core Viewpoint - Enhua Pharmaceutical has entered into exclusive commercial cooperation agreements with Shandong Green Leaf Pharmaceutical and its subsidiary, allowing Enhua to promote and sell three long-acting antipsychotic injectable products in mainland China [1] Group 1: Agreement Details - Enhua's subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., will receive exclusive rights to promote and sell three products: Risperidone microspheres (Riketu®), Paliperidone palmitate injection (Ruibailai®), and Paliperidone palmitate injection (Meibiri®) [1] - Enhua will make a one-time non-refundable payment of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaao as compensation for the rights and licenses granted under the agreement [1] - Enhua is committed to achieving a total sales revenue of no less than 2.7 billion RMB (including tax) for the cooperative products from 2026 to 2035 [1] Group 2: Financial Arrangements - Green Leaf Pharmaceutical and Green Leaf Jiaao will pay Enhua service fees based on the procurement and sales performance of the licensed products [1]